- Home
- VANI vs BBIO Comparison
VANI vs BBIO Comparison
Compare VANI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- BBIO
- Stock Information
- Founded
- VANI 1998
- BBIO 2015
- Country
- VANI United States
- BBIO United States
- Employees
- VANI N/A
- BBIO N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- BBIO Health Care
- Exchange
- VANI Nasdaq
- BBIO Nasdaq
- Market Cap
- VANI 68.1M
- BBIO 8.0B
- IPO Year
- VANI 2014
- BBIO 2019
- Fundamental
- Price
- VANI $1.26
- BBIO $42.78
- Analyst Decision
- VANI Strong Buy
- BBIO Strong Buy
- Analyst Count
- VANI 1
- BBIO 14
- Target Price
- VANI $4.00
- BBIO $58.85
- AVG Volume (30 Days)
- VANI 154.9K
- BBIO 3.3M
- Earning Date
- VANI 08-12-2025
- BBIO 07-31-2025
- Dividend Yield
- VANI N/A
- BBIO N/A
- EPS Growth
- VANI N/A
- BBIO N/A
- EPS
- VANI N/A
- BBIO N/A
- Revenue
- VANI N/A
- BBIO $127,415,000.00
- Revenue This Year
- VANI N/A
- BBIO $102.05
- Revenue Next Year
- VANI N/A
- BBIO $54.69
- P/E Ratio
- VANI N/A
- BBIO N/A
- Revenue Growth
- VANI N/A
- BBIO N/A
- 52 Week Low
- VANI $0.91
- BBIO $21.72
- 52 Week High
- VANI $1.50
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- VANI 67.52
- BBIO 62.54
- Support Level
- VANI $1.28
- BBIO $39.65
- Resistance Level
- VANI $1.33
- BBIO $45.48
- Average True Range (ATR)
- VANI 0.07
- BBIO 1.56
- MACD
- VANI 0.01
- BBIO 0.15
- Stochastic Oscillator
- VANI 79.55
- BBIO 60.90
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.